Segment Information (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
|
Sep. 30, 2020
USD ($)
|
Sep. 30, 2019
USD ($)
|
Sep. 30, 2020
USD ($)
segment
|
Sep. 30, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
|
|
| Segment Reporting Information [Line Items] | |||||
| Number of Reportable Segments | segment | 2 | ||||
| Net Revenue | $ 9,475 | $ 9,772 | $ 31,850 | $ 25,499 | |
| Income (loss) from operations | (23,043) | (22,540) | (69,967) | (80,438) | |
| Intangible asset, net | 11,039 | 11,039 | $ 7,377 | ||
| Dermatology Products Sales [Member] | |||||
| Segment Reporting Information [Line Items] | |||||
| Net Revenue | 9,447 | 9,492 | 30,808 | 23,816 | |
| Direct cost of goods | (3,379) | (2,702) | (10,313) | (6,972) | |
| Sales and marketing costs | (4,649) | (4,370) | (12,728) | (12,064) | |
| Research and development | 0 | 0 | |||
| General and administrative | (1,254) | (669) | (3,556) | (1,808) | |
| Other expense | (113) | (108) | (492) | (108) | |
| Income (loss) from operations | 52 | 1,643 | 3,719 | 2,864 | |
| Intangible asset, net | 11,039 | 7,731 | 11,039 | 7,731 | |
| Tangible assets | 21,108 | 10,966 | 21,108 | 10,966 | |
| Total segment assets | 32,147 | 18,697 | 32,147 | 18,697 | |
| Pharmaceutical and Biotechnology Product Development [Member] | |||||
| Segment Reporting Information [Line Items] | |||||
| Net Revenue | 28 | 280 | 1,042 | 1,683 | |
| Direct cost of goods | 0 | 0 | |||
| Sales and marketing costs | 0 | 0 | |||
| Research and development | (13,756) | (15,271) | (46,146) | (57,705) | |
| General and administrative | (9,480) | (9,300) | (29,074) | (27,388) | |
| Other expense | (6,808) | (2,322) | (12,036) | ||
| Other expense | 11,841 | ||||
| Income (loss) from operations | (30,016) | (26,613) | (86,214) | (71,569) | |
| Intangible asset, net | 0 | 0 | 0 | 0 | |
| Tangible assets | 263,732 | 202,891 | 263,732 | 202,891 | |
| Total segment assets | 263,732 | 202,891 | 263,732 | 202,891 | |
| Consolidated [Member] | |||||
| Segment Reporting Information [Line Items] | |||||
| Net Revenue | 9,475 | 9,772 | 31,850 | 25,499 | |
| Direct cost of goods | (3,379) | (2,702) | (10,313) | (6,972) | |
| Sales and marketing costs | (4,649) | (4,370) | (12,728) | (12,064) | |
| Research and development | (13,756) | (15,271) | (46,146) | (57,705) | |
| General and administrative | (10,734) | (9,969) | (32,630) | (29,196) | |
| Other expense | (6,921) | (2,430) | (12,528) | ||
| Other expense | 11,733 | ||||
| Income (loss) from operations | (29,964) | (24,970) | (82,495) | (68,705) | |
| Intangible asset, net | 11,039 | 7,731 | 11,039 | 7,731 | |
| Tangible assets | 284,840 | 213,857 | 284,840 | 213,857 | |
| Total segment assets | $ 295,879 | $ 221,588 | $ 295,879 | $ 221,588 | |
| X | ||||||||||
- Definition The amount of assets including assets held for sale. No definition available.
|
| X | ||||||||||
- Definition Other Operating Cost and Expense No definition available.
|
| X | ||||||||||
- Definition Tangible assets. No definition available.
|
| X | ||||||||||
- Definition Cost of product sold and service rendered, excluding depreciation, depletion, and amortization. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|